Sanofi Presents Four-Year IKEMA Trial Data for Sarclisa in Multiple Myeloma

Sanofi today presented four-year follow-up data from the Phase 3 IKEMA trial evaluating Sarclisa (isatuximab-irfc) plus carfilzomib and dexamethasone (Kd) in patients with relapsed or refractory multiple myeloma. The data showed that the progression-free survival benefit of isatuximab-Kd over Kd alone was maintained at four years, with a median PFS of 35.7 months versus 19.2 months.